Sanjivani Paranteral Ltd Q1 FY27 Earnings Analysis

- FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. - Base business expected to grow steadily with export operations normalizing and continued expansion in export markets. - Injectable segment growth: 10%-12% expected. - Tablet segment growth: 7%-8% expected, with increasing product dossiers and portfolio expansion over 2-3 years. - Nutraceutical business to ramp up gradually with improved traction in FY'27. - Pune IV plant ramp-up: production to increase to 70% utilization by Q4 FY'27, aiming for INR 60 crores annual revenue. - Long-term: steady increase in injectable and substantial growth in tablets and capsules expected over next 2-3 years. - Growth impacted recently by geopolitical and logistical challenges, but alternative routes established to support recovery.

- For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions. - The new Pune IV infusion plant aims for an annual revenue of around INR 60-65 crores with EBITDA margins of 17% to 18%, expected to ramp up utilization from 40% in Q1 to 70% in Q4 FY'27. - PAT margins will mirror EBITDA margin improvements as higher-margin products enter the portfolio. - The nutraceutical venture (Prague-based) is expected to show improved commercial traction and contribute profits in FY'27. - Overall, FY'27 is expected to be stronger with growth and margin expansion driven by all three verticals: base injectable business, IV infusion plant, and nutraceuticals. - Management remains optimistic about medium to long-term earnings growth fueled by export market expansion and new product approvals.

- The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025. - The Pune plant has an annual installed capacity of 60 million bottles, with ramp-up expected to reach 70% utilization by Q4 FY '27. - Expected revenue from the Pune IV plant for FY '27 is around INR 60-65 crores with EBITDA margins of 17-18%. - There is ongoing work on dossier filings and approvals for new products, including those for the Pune plant; pipeline approvals were expected by early 2026 but delayed due to regulatory changes. - The company is also invested in Prague Ventures (nutraceuticals), owning 45% with plans to increase stake to majority in the future; commercial activities and revenue growth expected in FY '27. - No explicit mention of further large-scale new capex was noted beyond this ongoing plant scale-up and portfolio expansion.

- The transcript does not mention any current or planned fundraising through debt or equity. - No discussions or questions related to raising capital via equity or debt instruments were addressed during the call. - The focus was primarily on operational performance, margin guidance, scale-up of the Pune IV plant, and geographic/product portfolio expansion. - The company emphasized improving margins, scaling new product lines, and managing working capital internally without indicating external fund-raising plans.

- Pune IV facility currently has 5 product approvals and 18 products in the pipeline. - Approval delays have occurred due to government staff transfers and stricter approval processes. - A significant portion of approvals (a "quite chunk") is expected to be received in the current month (May 2026). - Out of the 18 products in the pipeline for the Pune plant, about 6 are expected to contribute to revenue. - Pune IV plant is targeting around INR 60 crore in annual revenue, reflecting a ramp-up and commercial scale-up of new products. - The nutraceutical venture (Prague Ventures) is ramping up with a good order book in the current year. - Overall, the company expects stronger momentum with product portfolio expansion and increased commercialization in FY '27.